Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)
- Authors: Pshenichnaya NY.1, Bulgakova VA2, Lvov NI3, Poromov AA4, Selkova EP5, Grekova AI6, Shestakova IV7, Maleev VV1, Leneva IA8
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Children’s Health Research Centre, Ministry of Health of Russia
- S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation
- M.V. Lomonosov Moscow State University
- G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Smolensk State Medical University, Ministry of Health of Russia
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
- I.I. Mechnikov Research Institute of Vaccines and Sera
- Issue: Vol 91, No 3 (2019)
- Pages: 56-63
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33014
- DOI: https://doi.org/10.26442/00403660.2019.03.000127
- ID: 33014
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N Yu Pshenichnaya
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfareд.м.н., проф., в.н.с. клинического отд. инфекционной патологии ФБУН «ЦНИИ эпидемиологии» Роспотребнадзора
V A Bulgakova
Children’s Health Research Centre, Ministry of Health of Russiaд.м.н., г.н.с. отдела прогнозирования и планирования научных исследований ФГАУ «Научный центр здоровья детей» Минздрава России; ORCID: 0000-0003-4861-0919
N I Lvov
S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federationд.м.н., доцент, проф. каф. инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний) ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России; ORCID: 0000-0003-4254-229Х
A A Poromov
M.V. Lomonosov Moscow State Universityк.б.н., н.с. ФГБОУ ВПО «МГУ им. М.В. Ломоносова»; ORCID: 0000-0002-2004-3935
E P Selkova
G.N. Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfareд.м.н., проф., зам. директора ФБУН «Московский НИИ эпидемиологии и микробиологии им. Г.Н. Габричевского» Роспотребнадзора
A I Grekova
Smolensk State Medical University, Ministry of Health of Russiaк.м.н., доцент, зав. каф. инфекционных болезней у детей ФГБОУ ВО «СГМУ» Минздрава России
I V Shestakova
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russiaд.м.н., проф. каф. инфекционных болезней и эпидемиологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»
V V Maleev
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfareакад. РАН, д.м.н., проф., зам. директора института по научной работе ФБУН ЦНИИ эпидемиологии Роспотребнадзора
I A Leneva
I.I. Mechnikov Research Institute of Vaccines and Sera
Email: wnyfd385@yandex.ru
д.б.н., зав. лаб. экспериментальной вирусологии ФГБНУ «НИИ вакцин и сывороток им. И.И. Мечникова»; тел.: +7(495)917-49-00; e-mail: wnyfd385@yandex.ru; ORCID: 0000-0002-7755-2714
References
- Monto A.S. Epidemiology of viral respiratory infections. Am J Med. 2002 Apr 22;112(Suppl 6A):4S-12S.
- Cox N.J, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med. 2000;51:407-21.
- World Health Organization. Influenza (seasonal). 2016. http://www.who.int/mediacentre/factsheets/fs211/en/ Accessed 12.12.2017.
- Хасанова Р.Р. Динамика смертности населения от болезней органов дыхания и гриппа в современной России. Проблемы анализа риска. 2017;14(5):72-81.
- Maltezou H.C, Tsiodras S. Antiviral agents for influenza: molecular targets, concerns of resistance, and new treatment options. Curr Drug Targets. 2009 Oct;10(10):1041-8.
- World Health Organization. Influenza: BRaVe call to action. 2013. http://www.who.int/influenza/patient_care/clinical/call_to_action/en/ Accessed 12.12.2017.
- Ison M.G. Finding the right combination antiviral therapy for influenza. Lancet Infect Dis. 2017 Dec;17(12):1221-2. doi: 10.1016/S1473-3099(17)30537-6. Epub 2017 Sep 22
- Oshansky C.M, Thomas P.G. The human side of influenza. J Leukocyte Biology. 2012;92(1):83-96. doi: 10.1189/jlb.1011506
- Ramos I, Fernandez-Sesma A. Innate Immunity to H5N1 Influenza Viruses in Humans. Viruses. 2012;4(12):3363-88. doi: 10.3390/v4123363
- Teijaro J.R, Walsh K.B, Long J.P, Tordoff K.P, Stark G.V, Eisfeld A.J, et al. Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy. Virology. 2014 Mar;452-453:152-7. doi: 10.1016/j.virol.2014. 01.003. Epub 2014 Jan 31
- Webster R.G, Govorkova E.A. Continuing challenges in influenza. Annals of the New York Academy of Sciences. 2014;1323(1):115-39. doi: 10.1111/nyas.12462
- Osterholm M.T, Kelley N.S, Sommer A, Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta - analysis. Lancet Infect Dis. 2012 Jan;12(1):36-44. doi: 10.1016/S1473-3099(11)70295-X
- Guidance for Industry Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). June 2006. https://www.fda.gov/ohrms/dockets/98fr/05d-0183-gdl0002-01.pdf
- Beigel J.H. Antiviral compounds in the pipeline to tackle H1N1 influenza infection. Drugs of the future. 2010;35(5):385-92. doi: 10.1358/dof.2010.035. 05.1487081
- Intharathep P, Laohpongspaisan C, Rungrotmongkol T, Loisruangsin A, Malaisree M, Decha P, Aruksakunwong O, Chuenpennit K, Kaiyawet N, Sompornpisut P, Pianwanit S, Hannongbua S. How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model. 2008 Oct;27(3):342-8. doi: 10.1016/j.jmgm.2008.06.002
- Van der Vries E, van den Berg B.W, Schutten M. Fatal oseltamivir - resistant influenza virus infection. New England J Medicine. 2008;359(10):1074-6. doi: 10.1056/NEJMc0803120
- Gubareva L.V, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infectious Diseases. 2001;183:523-31. doi: 10.1086/318537
- Yacine A, Boivin G. A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open forum infectious diseases. Oxford University Press. 2017;4(3):1-10. https://doi.org/10. 1093/ofid/ofx105
- Trebbien R, Pedersen S.S, Vorborg K, Franck K.T, Fischer T.K. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Eurosurveillance. 2017;22(3):30445. doi: 10.2807/1560-7917.ES.2017.22.3.30445
- Zeng L.Y, Yang J, Liu S. Investigational hemagglutinin - targeted influenza virus inhibitors. Expert Opin Investig Drugs. 2017 Jan;26(1):63-73. doi: 10.1080/13543784.2017.1269170
- Boriskin Y.S, Leneva I.A, Pécheur E.I, Polyak S.J. Arbidol: a broad - spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997-1005. doi: 10.2174/092986708784049658
- Nasser Z.H, Swaminathan K, Müller P, Downard K.M. Inhibition of influenza hemagglutinin with the antiviral inhibitor arbidol using a proteomics based approach and mass spectrometry. Antiviral Res. 2013;100(2):399-406. doi: 10.1016/j.antiviral.2013.08.021
- Blaising J, Polyak S.J, Pécheur E.I. Arbidol as a broad - spectrum antiviral: an update. Antiviral Res. 2014;107:84-94. doi: 10.1016/j.antiviral.2014.04.006
- Kadama R.U and Wilson I.A. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci USA. 2017;114(2):206-14. doi: 10.1073/pnas.1617020114
- Leneva I.A, Russell R.J, Boriskin Y.S, Hay A.J. Characteristics of arbidol - resistant mutants of influenza virus: implications for the mechanism of anti - influenza action of arbidol. Antiviral Res. 2009,81(2):132-40. doi: 10.1016/j. antiviral.2008.10.009
- Львов Д.К., Бурцева Е.И., Щелканов М.Ю. и др. Особенности эпидемии гриппа на отдельных территориях России в эпидемическом сезоне 2012-2013 гг. Доминирование штаммов вируса гриппа А(Н1N1)pdm09 в странах Европы. Вопросы вирусологии. 2014;2:5-10.
- Huang L, Zhang L, Liu Y, Luo R, Zeng L, Telegina I, Vlassov V. Arbidol for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews. 2015;1. doi: 10.1002/14651858.CD011489
- Bulgakova V.A, Uchaikin V.F, Shamsheva O.V, Osipova E.A, Bevz A.Y, Prostyakov I.V, Maleev V.V. Pharmacologic and Epidemiologic Study of the Course of Influenza and Other Acute Respiratory Viral Infections in Postpandemic Season in Children Younger than 18 years. J Pediatric Infectious Diseases. 2015;10(03):68-75. doi: 10.1055/s-0036-1571306
- Leneva I.A, Burtseva E.I, Yatsyshina S.B, Fedyakina I.T, Kirillova E.S, Selkova E.P, Osipova E, Maleev V.V. Virus susceptibility and clinical effectiveness of anti - influenza drugs during the 2010-2011 influenza season in Russia. Int J Infect Dis. 2016;43:77-84. doi: 10.1016/j.ijid.2016.01.001
- Brooks M.J, Sasadeusz J.J, Tannock G.A. Antiviral chemotherapeutic agents against respiratory viruses: wh ere are we now and what’s in the pipeline. Curr Opin Pulmonary Med. 2004;10:197.
- Megan J. Brooks, Elena I. Burtseva, et al. Antiviral Activity of Arbidol, a Broad-Spectrum Drug for Use Against Respiratory Viruses, Varies According to Test Conditions. J Med Virol. 2012 Jan;84(1):170-81.
- Ленёва И.А. Механизм вирус - специфического действия препарата Арбидол: Дис…. д.б.н.: 03.00.06 М., 2005:303 с. РГБ ОД, 71:06-3/135.
- Pécheur E.I, Borisevich V, Halfmann P, Morrey J.D, Smee D.F, Prichard M, et al. The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol. 2016 Jan 6;90(6):3086-92. doi: 10.1128/JVI.02077-15
- Киселев О.И., Малеев В.В., Деева Э.Г., Ленёва И.А., Селькова Е.П., Осипова Е.А., Обухов А.А., Надоров С.А., Куликова Е.В. Клиническая эффективность препарата Арбидол (умифеновир) в терапии гриппа у взрослых: промежуточные результаты многоцентрового двойного слепого рандомизированного плацебо - контролируемого исследования АРБИТР. Терапевтический архив. 2015;87(1):88-96. doi: 10.17116/terarkh201587188-96
- Evans S.J.W. Pharmacoepidemiology. British J Clinical Pharmacology. 2012;73(6):973-8. doi: 10.1111/j.1365-2125.2012. 04248.x
- Berger M.L, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand S.L. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012 Mar-Apr;15(2):217-30. doi: 10.1016/j.jval.2011.12.010
- Малеев В.В., Селькова Е.П., Простяков И.В., Осипова E.A. Фармакоэпидемиологическое исследование течения гриппа и других ОРВИ в сезоне 2010/11 гг. Инфекционные болезни. 2012;10(3):15-23.
- Булгакова В.А., Поромов А.А., Грекова А.И., Пшеничная Н.Ю., Селькова Е.П., Львов Н.И., Ленёва И.А., Шестакова И.В., Малеев В.В. Фармакоэпидемиологическое исследование течения гриппа и других ОРВИ в группах риска. Терапевтический архив. 2017;89(1):62-71. doi: 10.17116/terarkh201789162-71
![](/img/style/loading.gif)